Corbus Pharmaceuticals Holdings (CRBP) Enterprise Value (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Enterprise Value of -$163.3 million for Q4 2025, down 9.53% year-over-year from -$180.5 million in Q4 2024, and down 57.02% quarter-over-quarter from -$104.0 million in Q3 2025.
Corbus Pharmaceuticals Holdings (CRBP) Enterprise Value (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Enterprise Value history runs 13 years deep, the most recent figure standing at -$163.3 million for Q4 2025.
- In Q4 2025, Enterprise Value fell 9.53% year-over-year to -$163.3 million; the TTM figure through Dec 2025 stood at -$163.3 million (down 9.53% YoY), while the FY2025 annual figure was -$163.3 million, down 9.53% from the prior year.
- Enterprise Value for Q4 2025 stood at -$163.3 million, down from -$104.0 million in the prior quarter.
- The five-year high for Enterprise Value was -$20.9 million in Q4 2023, with the low at -$163.3 million in Q4 2025.
- The 5-year median for Enterprise Value is -$105.2 million (2021), against an average of -$97.1 million.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value surged 64.68% in 2023, then plunged 613.01% in 2024.
- Corbus Pharmaceuticals Holdings' Enterprise Value stood at -$97.6 million in 2021, then soared by 39.38% to -$59.2 million in 2022, then soared by 64.68% to -$20.9 million in 2023, then slumped by 613.01% to -$149.1 million in 2024, then slipped by 9.53% to -$163.3 million in 2025.
- Business Quant data shows CRBP's Enterprise Value at -$163.3 million in Q4 2025, -$104.0 million in Q3 2025, and -$116.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -3.31 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.16 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 2.12 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -18.39 Bn |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - | -163.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -163.27 Mn |
| Sep 30, 2025 | -103.98 Mn |
| Jun 30, 2025 | -116.59 Mn |
| Mar 31, 2025 | -132.79 Mn |
| Dec 31, 2024 | -149.06 Mn |
| Sep 30, 2024 | -159.36 Mn |
| Jun 30, 2024 | -147.03 Mn |
| Mar 31, 2024 | -120.10 Mn |
| Dec 31, 2023 | -20.91 Mn |
| Sep 30, 2023 | -28.73 Mn |
| Jun 30, 2023 | -36.57 Mn |
| Mar 31, 2023 | -44.23 Mn |
| Dec 31, 2022 | -59.20 Mn |
| Sep 30, 2022 | -66.23 Mn |
| Jun 30, 2022 | -73.30 Mn |
| Mar 31, 2022 | -86.12 Mn |
| Dec 31, 2021 | -97.65 Mn |
| Sep 30, 2021 | -106.86 Mn |
| Jun 30, 2021 | -106.45 Mn |
| Mar 31, 2021 | -124.01 Mn |